Cardiovascular Disease
Conditions
Interventions
breviscapine:breviscapine
Control:Placebo
Sponsors
SIR RUN RUN SHAW Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Coronary CT or Coronary angiograme verified at least one main vessel totally occlusion in left/right coronary artery.
Exclusion criteria
Exclusion criteria: 1. AMI in 1 week; 2. The target lesion was done PCI or CABG in the last 6 months; 3. Will have surgical operation(except CABG) in the future 6 months; 4. Cerebral infaction in the last 6 months; 5. Can not tolerate dual anti-platelet or statin therapy, or allergy to breviscapine; 6. Using breviscapine at this time; 7. Combine with server hepatic or respiratory dysfunction; 8. Heart Failure (NYHA IV), or EF3mg/dl or eGFR <40 ml/min/1.73 m2; 10. Combined with dilated cardiomyopathy, hypertrophic cardiomyopathy or server valvular heart disease; 11. Will or just using glucocorticoid; 12. Combined with malignant tumor; 13. Predicted survival <12 months; 14. Pregnancy test positive; 15. Participate in another clinical trial, or will participate in the future 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The comparation of viable myocardium at 12 months with baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| MACE;left ventricular remodeling;The comparation of viable myocardium at 1 months with baseline;The comparation of microcirculatory perfusion at 1/12 months with baseline;VEGF and bFGF concentration at peripheral blood; | — |
Countries
China
Contacts
Public ContactWENBIN ZHANG
SIR RUN RUN SHAW Hospital
Outcome results
None listed